CAMP4 Therapeutics Corp

CalAmp Corp. engages in delivering of wireless access and computer technologies. It provides Internet of Things (IoT) enablement solutions for a broad array of mobile and fixed applications serving multiple vertical markets worldwide. It offers solutions for mobile resource management and applications for the broader IoT market, enabling customers to optimize their operations by collecting, monitoring and efficiently reporting business-critical data and desired intelligence from high-value remote and often mobile assets. The company segments include Telematics System and Software and Subscription Services. CalAmp was founded in 1981 and is headquartered in Irvine, CA.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q2 2025

CalAmp Corp. engages in the provision of wireless access and computer technologies. It operates through the Software and Subscription Services, and Telematics Products segments. The Software and Subscription Services segment offers solutions consisting of telematics devices bundled with cloud-based application enablement and telematics services. The Telematics Products segment focuses on telematics products for the broader connected vehicle and industrial IoT marketplace. The company was founded in 1981 and is headquartered in Irvine, CA.

- Completed Initial Public Offering (IPO) of common stock, raising gross proceeds of $82.1M- Single Ascending Dose (SAD) portion of Phase 1 study of CMP-CPS-001 completed; safety data anticipated in Q1 2025- Entered strategic research collaboration with BioMarin valued at over $370M

CAMP4 Reports Third Quarter 2024 Financial Results

In October, CAMP4 Therapeutics Corporation CAMP priced its initial public offering of 6.82 million at $11.00 per share, with approximately $75 million in gross proceeds.

CAMP4 Analyst Highlights Rare Disease Platform Potential

CAMBRIDGE, Mass., Oct. 10, 2024 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation (“CAMP4”) (Nasdaq: CAMP), a clinical-stage biotechnology company developing a pipeline of regulatory RNA-targeting therapeutics designed to upregulate gene expression with the goal of restoring healthy protein levels across a range of genetic diseases, today announced the pricing of its initial public offering of 6,820,000 shares of its common stock at an initial public offering price of $11.00 per share. All of the shares are being offered by CAMP4. The gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses, are expected to be approximately $75.0 million. CAMP4's common stock is expected to begin trading on the Nasdaq Global Market on October 11, 2024, under the ticker symbol “CAMP”. The offering is expected to close on October 15, 2024, subject to the satisfaction of customary closing conditions. In addition, CAMP4 has granted the underwriters a 30-day option to purchase up to an additional 1,023,000 shares of common stock at the initial public offering price, less underwriting discounts and commissions.

CAMP4 Announces Pricing of Initial Public Offering

Camp4 Therapeutics is seeking $75 million in an IPO to fund the advancement of its clinical-stage biopharma programs targeting genetic disorders. CAMP's lead candidate, CMP-CPS-001, has shown positive Phase 1 safety results for treating urea cycle disorders, with no concerning safety trends observed. The urea cycle disorders market is moderate in size, with a low expected growth rate, but Camp4 aims to broaden into larger markets.

News for CAMP4 Therapeutics Corp Stock (CAMP)